%0 Journal Article %T Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance %+ Sino-French Cooperative Central Lab [Shanghai, China] %+ Department of Ultrasound [Shanghai, China] %+ Shanghai Institutes for Biological Sciences %+ Clinical laboratory [Shanghai, China] %+ Les cellules souches : de leurs niches à leurs applications thérapeutiques %A Wang, Ying %A Liu, Qiuyun %A Chen, Haojie %A You, Jun %A Peng, Bin %A Cao, Fanfan %A Zhang, Xue %A Chen, Qing %A Uzan, Georges %A Xu, Limin %A Zhang, Denghai %< avec comité de lecture %@ 0959-4973 %J Anti-Cancer Drugs %I Lippincott, Williams & Wilkins %V 29 %N 8 %P 748-755 %8 2018 %D 2018 %R 10.1097/CAD.0000000000000647 %M 29927769 %Z Life Sciences [q-bio]Journal articles %X The development of resistance to therapy continues to be a serious clinical problem in lung cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is one of the most common chemotherapy drugs to treat non-small-cell lung cancer. However, almost all treatments fail after ∼1 year of treatment because of drug tolerance, probably occurring from the threonine 790 mutation (T790M) of the EGFR, resulting in overactivation of the EGFR. Celastrol is a natural compound that exhibits antiproliferative activity. In this study, we showed that celastrol combined with EGFR-TKIs significantly suppressed cell invasion of lung cancer cells with a T790M mutation by suppressing the EGFR pathway. Combined therapy with celastrol and EGFR-TKIs inhibited tumor growth in vivo. Together, these results suggested that combined therapy with EGFR-TKIs and celastrol may be a more effective treatment of patients with non-small-cell lung cancer with T790M mutations of the EGFR. %G English %L inserm-02402025 %U https://inserm.hal.science/inserm-02402025 %~ INSERM %~ UNIV-PSUD %~ UNIV-PARIS-SACLAY %~ UNIV-PSUD-SACLAY